Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results